Valuation dashboard for ICON Public Limited Company (ICLR) with P/E 49.61, P/B 2.09, EV/EBITDA 14.11 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Analysis Summary
ICON Public Limited Company reported revenue of $8.25B in the most recent fiscal year, growing at a 5-year CAGR of 24.2%. Net income reached $229.3M, with a -6.9% 5-year CAGR.
Trailing-twelve-month margins: gross margin 21.2%, operating margin 9.5%, net margin 5.4%.
At $211.36 (closing price, October 30, 2026), ICLR trades at a P/E of 49.61 and an ROE of 4.85%. Market capitalisation stands at $16.3B, placing it among large-cap names.
Balance sheet quality for ICLR: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 49.61 |
| Price / Book | 2.09 |
| EV / EBITDA | 14.11 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $168.13 |
| vs Current Price | -20.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ICLR | ICON Public Limited Company | $16.3B | 49.61 | 2.09 | 4.9% |
| MEDP | Medpace Holdings, Inc. | $18.2B | 38.20 | 31.14 | 99.8% |
| FTRE | Fortrea Holdings Inc. | $2.0B | 4.15 | -12.8% | |
| IQV | IQVIA Holdings Inc. | $44.1B | 33.17 | 6.61 | 21.8% |
| LH | Labcorp Holdings Inc. | $29.3B | 29.65 | 3.31 | 11.5% |
| CRL | Charles River Laboratories International, Inc. | $17.3B | 6.10 | -7.7% |
Price
| Price | $211.36 (closing price, October 30, 2026) |
| Market Cap | $16.3B |
| Exchange | NASDAQ |
| Country | IE |
Profitability
| Return on Equity | 4.85% |
| Return on Invested Capital | 4.85% |
| Return on Assets | 2.76% |
| Gross Margin | 21.19% |
| Operating Margin | 9.46% |
| Net Margin | 5.45% |
Related companies: MEDP · FTRE · IQV · LH · CRL
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of ICLR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks